Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AstraZeneca, Dynavax extend respiratory disease research collaboration
April 2009
SHARING OPTIONS:

LONDON—AstraZeneca PLC and Dynavax Technologies Corp. announced in March that they have extended their collaboration on the development of novel therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
 
The $136 million agreement, launched in September 2006, will now continue until July 2010. The partnership's first candidate drug, AZD1419, is expected to enter Phase 1 clinical development in the second half of 2009. The companies are currently working on a second candidate drug, and this extension includes research funding for a third candidate drug.
 
Dynavax's pipeline of novel toll-like receptor-based product candidates specifically modify the body's innate immune response to infectious, respiratory, autoimmune and inflammatory diseases.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.